Corcept Therapeutics Incorporated (NASDAQ:CORT) has coverage initiated with a Hold rating and $17.00 price target

ME Staff
-
0

Analyst Ratings For Corcept Therapeutics Incorporated (NASDAQ:CORT)

Today, Cantor Fitzgerald initiated coverage on Corcept Therapeutics Incorporated (NASDAQ:CORT) with a Hold with a price target of $17.00.

There are 3 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Corcept Therapeutics Incorporated (NASDAQ:CORT) is Buy with a consensus target price of $22.40 per share, a potential 62.20% upside.

Some recent analyst ratings include

  • 8/23/2018-Corcept Therapeutics Incorporated (NASDAQ:CORT) has coverage initiated with a Hold rating and $17.00 price target
  • 8/10/2018-Corcept Therapeutics Incorporated (NASDAQ:CORT) had its Hold rating reiterated by Stifel Nicolaus with a $11.00 price target
  • 4/13/2018-Corcept Therapeutics Incorporated (NASDAQ:CORT) has coverage initiated with a Buy rating and $32.00 price target
  • 12/20/2016-Corcept Therapeutics Incorporated (NASDAQ:CORT) has coverage initiated with a Sell rating and $7.00 price target

Recent Insider Trading Activity For Corcept Therapeutics Incorporated (NASDAQ:CORT)
Corcept Therapeutics Incorporated (NASDAQ:CORT) has insider ownership of 15.00% and institutional ownership of 80.00%.

  • On 8/20/2018 G Leonard Baker Jr, Director, bought 35,681 with an average share price of $12.92 per share and the total transaction amounting to $460,998.52.
  • On 8/17/2018 G Leonard Baker Jr, Director, bought 105,792 with an average share price of $12.50 per share and the total transaction amounting to $1,322,400.00.
  • On 8/15/2018 G Leonard Baker Jr, Director, bought 179,686 with an average share price of $12.48 per share and the total transaction amounting to $2,242,481.28.
  • On 8/7/2018 Robert S Fishman, Insider, sold 8,000 with an average share price of $14.15 per share and the total transaction amounting to $113,200.00.
  • On 7/6/2018 Robert S Fishman, Insider, sold 8,000 with an average share price of $15.09 per share and the total transaction amounting to $120,720.00.
  • On 6/7/2018 Robert S Fishman, Insider, sold 8,000 with an average share price of $18.23 per share and the total transaction amounting to $145,840.00.
  • On 5/11/2018 G Leonard Baker Jr, Director, sold 30,000 with an average share price of $16.01 per share and the total transaction amounting to $480,300.00.

About Corcept Therapeutics Incorporated (NASDAQ:CORT)
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Recent Trading Activity for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Shares of Corcept Therapeutics Incorporated closed the previous trading session at 13.81 up +0.16 1.17% with shares trading hands.